Dual-action support
Approach appetite support through two pathways
Stronger appetite support, from two directions.
If you are ready for a broader approach to weight and appetite support, tirzepatide works across both GIP and GLP-1 pathways. The once-weekly routine may help quiet cravings, support fullness, and make your goals feel more within reach.

Approach appetite support through two pathways
Feel more satisfied and less pulled by cravings
Build consistency around a simple weekly routine
People who want a more comprehensive option for appetite, weight, and metabolic support.
Unlike semaglutide, tirzepatide works across both GIP and GLP-1 pathways for a dual-action approach.
In SURMOUNT-1, adults without diabetes received once-weekly tirzepatide or placebo alongside lifestyle intervention for 72 weeks.
SURMOUNT-1 (N=2,539). Results shown for the 15 mg treatment group do not establish expected results for a compounded product. Individual results vary. Jastreboff AM et al. N Engl J Med. 2022;387:205–216.
This drug is compounded by a licensed pharmacy in accordance with Section 503A of the Federal Food, Drug & Cosmetic Act and may be dispensed only under a patient-specific prescription issued by a licensed practitioner following a medical evaluation. FDA does not review or approve compounded medications for safety, effectiveness, or quality. Individual results may vary. This compounded formulation is not affiliated with, endorsed or approved by, or intended to replace products manufactured by Eli Lilly. Actual product packaging may differ from images shown.